Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 May 25;45(6):648-654.
doi: 10.3785/j.issn.1008-9292.2016.11.15.

[Research progress on disease models and gene therapy of Duchenne muscular dystrophy]

[Article in Chinese]
Tongyu Li  1 , Ping Liang  2
Affiliations
Review

[Research progress on disease models and gene therapy of Duchenne muscular dystrophy]

[Article in Chinese]
Tongyu Li et al. Zhejiang Da Xue Xue Bao Yi Xue Ban. .

Abstract
in English, Chinese

Duchenne muscular dystrophy (DMD) is an X-linked, recessive and lethal genetic disease, which usually caused by gene mutations and the underlying mechanisms are complicated and diverse. The causal gene of DMD is the largest one in human that locates in the region of Xp21.2, encoding dystrophin. Currently there is no effective treatment for DMD patients. The treatment of DMD depends on gene mutation and molecular mechanism study of the disease, which requires reliable disease models such as mdx mouse model. Recently, researchers have increasingly discovered gene therapy strategies for DMD, and the efficacy has been demonstrated in DMD animal models. In addition, induced pluripotent stem cell technology can provide patient-specific cell source, offering a new platform for mechanism and therapy study of DMD.

杜氏肌营养不良（DMD）是一种X连锁隐性致死性遗传病，通常由基因突变致病，其发病机制复杂多样。该病的致病基因是人类最大的基因，位于Xp21.2区，编码抗肌萎缩蛋白。目前，DMD患者尚无有效的治疗方案。DMD的基因突变及分子机制研究可为其治疗研究打下基础，而后者的进行又需建立在DMD疾病模型之上，如mdx小鼠模型等。随着研究的深入，DMD基因治疗策略不断提出，并在动物模型上取得了不错的效果。除此之外，诱导多能干细胞技术可提供患者特异的细胞来源，为DMD发病机制及治疗研究提供新的平台。

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. GOVONI A, MAGRI F, BRAJKOVIC S, et al. Ongoing therapeutic trials and outcome measures for Duchenne muscular dystrophy. Cell Mol Life Sci. 2013;70(23):4585–4602. doi: 10.1007/s00018-013-1396-z. [GOVONI A, MAGRI F, BRAJKOVIC S, et al. Ongoing therapeutic trials and outcome measures for Duchenne muscular dystrophy[J]. Cell Mol Life Sci, 2013, 70(23):4585-4602.] - DOI - PMC - PubMed
    1. DAVIES K E, SMITH T J, BUNDEY S, et al. Mild and severe muscular dystrophy associated with deletions in Xp21 of the human X chromosome. J Med Genet. 1988;25(1):9–13. doi: 10.1136/jmg.25.1.9. [DAVIES K E, SMITH T J, BUNDEY S, et al. Mild and severe muscular dystrophy associated with deletions in Xp21 of the human X chromosome[J]. J Med Genet, 1988, 25(1):9-13.] - DOI - PMC - PubMed
    1. KUNKEL L M, MONACO A P, MIDDLESWORTH W, et al. Specific cloning of DNA fragments absent from the DNA of a male patient with an X chromosome deletion. Proc Natl Acad Sci U S A. 1985;82(14):4778–4782. doi: 10.1073/pnas.82.14.4778. [KUNKEL L M, MONACO A P, MIDDLESWORTH W, et al. Specific cloning of DNA fragments absent from the DNA of a male patient with an X chromosome deletion[J]. Proc Natl Acad Sci U S A, 1985, 82(14):4778-4782.] - DOI - PMC - PubMed
    1. PRIOR T W, BRIDGEMAN S J. Experience and strategy for the molecular testing of Duchenne muscular dystrophy. J Mol Diagn. 2005;7(3):317–326. doi: 10.1016/S1525-1578(10)60560-0. [PRIOR T W, BRIDGEMAN S J. Experience and strategy for the molecular testing of Duchenne muscular dystrophy[J]. J Mol Diagn, 2005, 7(3):317-326.] - DOI - PMC - PubMed
    1. MAGRI F, GOVONI A, D'ANGELO M G, et al. Genotype and phenotype characterization in a large dystrophinopathic cohort with extended follow-up. J Neurol. 2011;258(9):1610–1623. doi: 10.1007/s00415-011-5979-z. [MAGRI F, GOVONI A, D'ANGELO M G, et al. Genotype and phenotype characterization in a large dystrophinopathic cohort with extended follow-up[J]. J Neurol, 2011, 258(9):1610-1623.] - DOI - PubMed